THQ Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.12%, SMA50 -0.92%, SMA200 5.56%). The stock’s 14-day RSI is 48.4 (neutral), while the ATR of 0.28 points to moderate volatility. The stock remains hovering near 52-week lows, trading -10.28% below its high and over 26.22% above its low. Average 10-day trading volume of 101.31 thousand shares is below the 3-month average of 202.30 thousand, indicating normal recent market interest.

Abrdn Healthcare Opportunities Fund (NYSE:THQ) closed at $18.92 USD, gaining $0.01 (0.05%) from the previous close of $18.91. The stock is currently mid-range between its 52-week high and low $16.28 and $20.39. With a market capitalization of about $784.00 million, Abrdn Healthcare Opportunities Fund is classified as a small-cap and shows market-like volatility (beta ~0.89). Key stats such as the average daily volume over the past year has been around 204.31 thousand shares, volume is running light vs its 52-week average. Headquartered in Philadelphia, PA, Abrdn Healthcare Opportunities Fund operates in the Financial Services sector and the Asset Management industry. Managed by Tekla Capital Management LLC, the Tekla Healthcare Opportunities Fund operates as a closed-end, balanced mutual fund.

Abrdn Healthcare Opportunities Fund last paid a dividend of 2.16 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$14.00. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Abrdn Healthcare Opportunities Fund stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

currently trading near 52-week highs band. Valuation shows Abrdn Healthcare Opportunities Fund trading at a premium to the broader market with a P/E of -27.05.

Abrdn Healthcare Opportunities Fund trades at a P/E ratio of -27.05, slightly below the S&P 500 average, with a price-to-sales ratio of 25.35 and a price-to-book ratio of 1.09 suggesting the stock is closer to book value. The P/FCF stands at -770.32, also below market averages.